•  
  •  
 

Abstract

ABSTRACT: BACKGROUND : Repaglinide belongs to the meglitinide class of blood glucose-lowering drugs. Repaglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the beta cells. This depolarizes the beta cells, opening the cells' calcium channels, and the resulting calcium influx induces insulin secretion. OBJECTIVE: To evaluate the effect of repaglinide as a monotherapy or in combination with metformin on controlling the fasting plasma glucose, postprandial plasma glucose, HBA1C, and body weight in 61 patients with type 2 diabetes mellitus, (DM). PATEINTS & METHODS: During the period between February 2005 and October 2005, the effects of repaglinide has been reviewed in 61 patients with uncontrolled Type 2 diabetes mellitus (T2DM), they are divided into two groups depending on their previous treatment , the 1st group included 43 of them were on metformin while the remaining 18 patients were on diet only. Weight, HBA1c, FPG and PPG were checked after 3 and 6 months. RESULTS: It has been found that six months after using Repaglinide in combination with metformin or as a monotherapy cause significant reduction in HBA1c, from 9.8 to 8.1% (P < 0.01) in 1st group, and from 7.9 to 6.7%, (P < 0.01) in 2nd group and a significant reduction of FPG from 214.0 mg/dl to 148.5 mg/dl (P < 0.01) in 1st group and from 170.7 mg/dl to 130 mg/dl (P < 0.01) in 2nd group. While the PPG shows a decrement from 255.6 mg/dl to 178.8 mg/dl, (P < 0.01) in 1st group and from 248.3 mg/dl to166.1 mg/dl (P < 0.01) in 2nd group. There’s no significant weight gain thus mean weight rose from 84.4 Kg to 84.6 Kg, (P > 0.2) in 1st group and from 75.1 kg to 76.1 kg (P > 0.2) in 2nd group . CONCLUSION: Repaglinide when used as monotherapy or in combination with metformin improve overall glycemic control and significantly reduced HBA1c but have no significant change in body weight

Download

Share

COinS